You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Statins, Diabetes and Glucose Metabolism: Challenging Cases and Considerations

  • Authors: Kausik K. Ray, MD, MPhil, FRCP; Henry N. Ginsberg, MD
  • CME / ABIM MOC / CE Released: 7/31/2018
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 7/31/2019
Start Activity


Target Audience and Goal Statement

This activity is intended for physicians, i.e, diabetologists and endocrinologists, cardiologists, primary care clinicians, nurses, and pharmacists who provide care for patients with cardiovascular disease (CVD) and who are at high risk for or with type 2 diabetes (T2D).

The goal of this activity is for learners to be better able to determine the appropriate use of statins to treat dyslipidemia in patients with CVD who are at high risk for or with T2D.

Upon completion of this activity, participants will:

  • Have greater competence related to
    • Treatment of dyslipidemia with statins in patients with CVD and at high risk for developing T2D
    • Treatment of dyslipidemia with statins in patients with CVD and T2D
    • How to address the elements of a multidisciplinary interprofessional care approach to the care for patients with CVD and at high risk for developing or with T2D


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Moderator

  • Kausik K. Ray, MD, MPhil, FRCP

    Professor of Public Health
    Honorary Consultant Cardiologist
    Imperial Centre for Cardiovascular Disease Prevention
    Department of Primary Care & Public Health
    Imperial College London
    London, United Kingdom

    Disclosures

    Disclosure: Kausik K. Ray, MD, MPhil, FRCP, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie Inc.; Amgen Inc.; Cerenis; Ionis; Lilly; Medco; Regeneron Pharmaceuticals, Inc.; Sanofi
    Served as a speaker or a member of a speakers bureau for: Alforithm; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; CIPLA; Kowa Company Ltd.; Pfizer Inc.; Takeda Pharmaceuticals North America, Inc.
    Received grants for clinical research from: Amgen Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi

    Dr Ray does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Ray does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelist

  • Henry N. Ginsberg, MD

    Irving Professor of Medicine
    Director Emeritus
    Irving Institute for Clinical and Translational Research
    Columbia University
    New York, New York

    Disclosures

    Disclosure: Henry N. Ginsberg, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Amgen Inc.; Ionis; Kowa Company Ltd.; Merck & Co., Inc.; Sanofi
    Received grants for clinical research from: Amgen Inc.

    Dr Ginsberg does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Ginsberg does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Steering Committee

  • Alan S. Brown, MD

    Director
    Advocate Heart Institute
    Advocate Lutheran General Hospital
    Park Ridge, Illinois

    Disclosures

    Disclosure: Alan S. Brown, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Akcea Therapeutics; Amgen Inc.; Kastle Therapeutics; Merck & Co., Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi
    Served as a speaker or a member of a speakers bureau for: Amgen Inc.; Kowa Company Ltd.; Regeneron Pharmaceuticals, Inc.; Sanofi

  • Harold Edward Bays, MD

    Medical Director
    Louisville Metabolic and Atherosclerosis Research Center
    Louisville, Kentucky

    Disclosures

    Disclosure: Harold Edward Bays, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Akcea Therapeutics; Alnylam Pharmaceuticals, Inc.; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Eisai Inc.; Esperion Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.; Janssen Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Kowa Company Ltd.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; ProSciento; Regeneron Pharmaceuticals, Inc.; Sanofi
    Served as a speaker or a member of a speakers bureau for: Amarin Corporation plc; Amgen Inc.; Eisai Inc.; Kowa Company Ltd.; Orexigen Therapeutics, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi
    Received grants for clinical research from: Alere; Allergan, Inc.; Amarin Corporation plc; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Catabasis Pharmaceuticals, Inc.; Chiltern; ChromaDex, Inc.; Dr. Reddy's Laboratories Ltd.; Eisai Inc.; Elcelyx Therapeutics, Inc.; Esperion Therapeutics, Inc.; Ferrer; Gemphire Therapeutics Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Home Access Health; Ionis Pharmaceuticals, Inc.; iSpecimen; Janssen Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Lilly; Merck & Co., Inc.; Nektar Therapeutics; Nichi-Iko Pharmaceutical Co., Ltd.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Omthera Pharmaceuticals, Inc.; Pfizer Inc; Regeneron Pharmaceuticals, Inc.; Sanofi; Selecta Biosciences, Inc.; Takeda Pharmaceuticals North America, Inc.; Timi Pharmaceuticals Corp.

  • Joseph L. Lillo, DO

    Assistant Professor
    Family Medicine
    Midwestern University College of Osteopathic Medicine
    Glendale, Arizona

    Disclosures

    Disclosure: Joseph L. Lillo, DO, has disclosed the following relevant financial relationships:
    Served as a speaker or a member of a speakers bureau for: Amarin Corporation plc; Amgen Inc.; Kowa Company Ltd.; Sanofi

  • Kevin C. Maki, PhD

    Chief Scientist
    Midwest Biomedical Research
    Wheaton, Illinois

    Disclosures

    Disclosure: Kevin C. Maki, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Akcea Therapeutics; Amgen Inc.; Kowa Company Ltd.; Regeneron Pharmaceuticals, Inc.; Sancilio & Company, Inc.

  • Kausik Ray, MD, MPhil, FRCP

    As listed above.

  • Joyce L. Ross, MSN, CRNP, CS

    Diplomate
    Accreditation Council for Clinical Lipidology
    Immediate Past President
    National Lipid Association
    Past President
    Preventive Cardiovascular Nurses Association
    Philadelphia, Pennsylvania

    Disclosures

    Disclosure: Joyce L. Ross, MSN, CRNP, CS, has disclosed the following relevant financial relationships:
    Served as a speaker or a member of a speakers bureau for: Amarin Corporation plc; Amgen Inc.; Kaneka Americas Holding, Inc.; Kowa Company Ltd.; Regeneron Pharmaceuticals, Inc.; Sanofi

Scientific Director

  • Joy P. Marko, MS, APN-C, CCMEP

    Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Joy P. Marko, MS, APN-C, CCMEP, has disclosed no relevant financial relationships.

  • Asha P. Gupta, PharmD, RPh

    Associate Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Asha P. Gupta, PharmD, RPh has disclosed no relevant financial relationships.

CME Reviewer / Nurse Planner

  • Amy Bernard, MS, BSN, RN-BC, CHCP

    Lead Nurse Planner, Medscape, LLC

    Disclosures

    Disclosure: Amy Bernard, MS, BSN, RN-BC, CHCP, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number JA0007105-0000-18-148-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Statins, Diabetes and Glucose Metabolism: Challenging Cases and Considerations

Authors: Kausik K. Ray, MD, MPhil, FRCP; Henry N. Ginsberg, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 7/31/2018

Valid for credit through: 7/31/2019

processing....

Abbreviations

ACC = American College of Cardiology

ACE = angiotensin-converting enzyme

ACS = acute coronary syndrome

ALT = alanine aminotransferase

apoB = apolipoprotein B

ART = antiretroviral therapy

ASCVD = atherosclerotic cardiovascular disease

AST = aspartate aminotransferase

AUC = area under the curve

BMI = body mass index

BP = blood pressure

CABG = coronary artery bypass grafting

CAD - coronary artery disease

CHD = coronary heart disease

CHF = congestive heart failure

CI = confidence interval

CV = cardiovascular

CVD = cardiovascular disease

DAPT = dual antiplatelet therapy

DM = diabetes mellitus

FDA = US Food and Drug Administration

FH = family history

GLP-1 = glucagon-like peptide 1

HbA1c = glycated hemoglobin

HDL = high-density lipoprotein

HDL-C = high-density lipoprotein cholesterol

HI = high-intensity statin therapy

HIV = human immunodeficiency virus

HMGCR = 3-hydroxy-3-methylglutaryl-CoA reductase

INR = international normalized ratio

LDL = low-density lipoprotein

LDL-C = low-density lipoprotein-cholesterol

LMI = low-moderate intensity statin therapy

MACE = major adverse cardiac events

MI = myocardial infarction

NHIS = National Health Interview Survey

NNT = number needed to treat

OR = odds ratio

OTC = over-the-counter

PAD = peripheral artery disease

PCI = percutaneous coronary intervention

RCT = randomized controlled trial

RR = relative risk

RRR = relative risk reduction

SGLT2 = sodium glucose cotransporter-2

STEMI = ST-elevation myocardial infarction

TC = total cholesterol

TG = triglycerides

TIA = transient ischemic attack

T2DM = type 2 diabetes mellitus

TLR = target lesion revascularization

UA = unstable angina

ULN = upper limit of normal

Vd = volume of distribution

« Return to: Statins, Diabetes and Glucose Metabolism: Challenging Cases and Considerations
  • Print